IL159524A0 - G-csf conjugates - Google Patents

G-csf conjugates

Info

Publication number
IL159524A0
IL159524A0 IL15952402A IL15952402A IL159524A0 IL 159524 A0 IL159524 A0 IL 159524A0 IL 15952402 A IL15952402 A IL 15952402A IL 15952402 A IL15952402 A IL 15952402A IL 159524 A0 IL159524 A0 IL 159524A0
Authority
IL
Israel
Prior art keywords
csf
conjugates
lysine residue
polypeptide
conjugated
Prior art date
Application number
IL15952402A
Other languages
English (en)
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27222576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL159524(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/904,196 external-priority patent/US6555660B2/en
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of IL159524A0 publication Critical patent/IL159524A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15952402A 2001-07-11 2002-07-10 G-csf conjugates IL159524A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/904,196 US6555660B2 (en) 2000-01-10 2001-07-11 G-CSF conjugates
DKPA200200447 2002-03-22
DKPA200200708 2002-05-08
PCT/DK2002/000482 WO2003006501A2 (en) 2001-07-11 2002-07-10 G-csf conjugates

Publications (1)

Publication Number Publication Date
IL159524A0 true IL159524A0 (en) 2004-06-01

Family

ID=27222576

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15952402A IL159524A0 (en) 2001-07-11 2002-07-10 G-csf conjugates

Country Status (16)

Country Link
US (4) US7550565B2 (ja)
EP (1) EP1425304B9 (ja)
JP (1) JP4444652B2 (ja)
KR (1) KR100961859B1 (ja)
AT (1) ATE468862T1 (ja)
AU (1) AU2002325819B2 (ja)
BR (1) BR0211071A (ja)
CA (1) CA2452582C (ja)
DE (1) DE60236522D1 (ja)
HU (1) HUP0400466A3 (ja)
IL (1) IL159524A0 (ja)
MX (1) MXPA04000231A (ja)
NO (1) NO20040093L (ja)
NZ (1) NZ530545A (ja)
PL (1) PL371781A1 (ja)
WO (1) WO2003006501A2 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CA2542179A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2549409C (en) * 2003-12-03 2013-10-29 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1948676A4 (en) * 2005-10-27 2011-05-25 Peptron Co Ltd CONJUGATE BASED ON BLOOD PROTEIN AND BIOACTIVE SUBSTANCE
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US20100183543A1 (en) * 2008-09-19 2010-07-22 Maxygen, Inc. Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
PL3248610T3 (pl) * 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
WO2011062862A1 (en) 2009-11-17 2011-05-26 Centocor Ortho Biotech Inc. Improved bacterial membrane protein secrection
WO2011068893A1 (en) 2009-12-02 2011-06-09 Amgen Inc. BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2542574B1 (en) 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
CN106714823A (zh) 2014-09-10 2017-05-24 克霖固鲁制药股份有限公司 适合神经系统疾病的治疗的hgf制剂
AU2016277147A1 (en) * 2015-06-11 2018-01-18 Ambio Pharmaceuticals, Llc Pegylated granulocyte colony stimulating factor (GCSF)
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209596C2 (de) * 1982-03-17 1985-10-03 Uni-Cardan Ag, 5200 Siegburg Gleichlaufdrehgelenk
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
JPS6263335A (ja) 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
ATE67517T1 (de) 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
CA1297004C (en) 1986-01-22 1992-03-10 Masahiko Tamura Pharmaceutical agent for promoting the recovery of hemopoietic capacity
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5681720A (en) * 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (de) 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5025388A (en) 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US20020177688A1 (en) 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5109119A (en) 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0546124B2 (en) 1990-08-29 2003-04-23 Genetics Institute, LLC Multidomain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
ATE263838T1 (de) 1991-02-26 2004-04-15 Astrazeneca Ab Vektor
US5157736A (en) 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
AU2408292A (en) 1991-07-11 1993-02-11 Regents Of The University Of California, The A method to identify protein sequences that fold into a known three-dimensional structure
US5386507A (en) 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU666866B2 (en) * 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
ATE195553T1 (de) 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
EP0670898B1 (en) * 1992-11-24 2003-10-08 G.D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5424963A (en) 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2720140B2 (ja) * 1993-02-03 1998-02-25 日東化学工業株式会社 フェニル基を有する光学活性α−ヒドロキシカルボン酸の製造法
EP0744409B9 (en) 1994-02-23 2009-08-19 Kyowa Hakko Kogyo Co., Ltd Platelet growth accelerator
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5576941A (en) * 1994-08-10 1996-11-19 York Technologies, Inc. Modular power supply system
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
AU705083B2 (en) 1995-10-05 1999-05-13 G.D. Searle & Co. Multi-functional hematopoietic receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CA2234059A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel c-mpl receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
CA2268742A1 (en) 1996-10-25 1998-04-30 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
JP2001527396A (ja) 1997-04-11 2001-12-25 ジー．ディー．サール アンド カンパニー ｆｌｔ３リガンドキメラタンパク質
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
IL139286A (en) 1998-04-28 2005-12-18 Applied Research Systems Polyol-ifn-beta conjugates, their preparation and use
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU6246599A (en) 1998-09-25 2000-04-17 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
ES2327606T3 (es) * 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
EP1354045A2 (en) 2000-09-07 2003-10-22 Eli Lilly And Company Hyperglycosylated polypeptides
AU9096001A (en) 2000-09-08 2002-03-22 Amgen Inc G-csf analog compositions and methods
GB0022877D0 (en) 2000-09-18 2000-11-01 Isis Innovation Analogues
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides

Also Published As

Publication number Publication date
HUP0400466A2 (hu) 2005-01-28
NZ530545A (en) 2006-10-27
WO2003006501A2 (en) 2003-01-23
EP1425304B1 (en) 2010-05-26
NO20040093L (no) 2004-03-09
HUP0400466A3 (en) 2006-01-30
DE60236522D1 (de) 2010-07-08
US20110020266A1 (en) 2011-01-27
EP1425304A2 (en) 2004-06-09
US7550565B2 (en) 2009-06-23
EP1425304B9 (en) 2010-09-08
US20070010660A1 (en) 2007-01-11
JP2005506317A (ja) 2005-03-03
US7550566B2 (en) 2009-06-23
KR100961859B1 (ko) 2010-06-09
US20060286068A1 (en) 2006-12-21
KR20040084884A (ko) 2004-10-06
AU2002325819B2 (en) 2008-06-19
US20060286069A1 (en) 2006-12-21
MXPA04000231A (es) 2004-05-04
PL371781A1 (en) 2005-06-27
ATE468862T1 (de) 2010-06-15
US7696153B2 (en) 2010-04-13
BR0211071A (pt) 2004-12-21
CA2452582C (en) 2013-01-22
WO2003006501A3 (en) 2004-03-25
JP4444652B2 (ja) 2010-03-31
CA2452582A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
IL159524A0 (en) G-csf conjugates
EA004789B9 (ru) Полимерные конъюгаты бета-1а-интерферона и их использование
SI1180121T1 (en) Long lasting insulinotropic peptides
MY139375A (en) Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BE2013C033I2 (ja)
PL2049566T3 (pl) Swoiste dla miejsca monokoniugaty G-CSF
HK1001190A1 (en) Tissue plasminogen activator glycosylation variants with improved therapeutic properties
IL196907A0 (en) Glycoprotein synthesis
NO984052L (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
IL130526A0 (en) Novel anti-allergenic agents